Patents by Inventor Qun Sun
Qun Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11510895Abstract: This document relates to non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising cabazitaxel and human serum albumin. This document also relates to compositions consisting essentially of cabazitaxel and human serum albumin.Type: GrantFiled: May 28, 2020Date of Patent: November 29, 2022Assignee: Zhuhai Beihai Biotech Co., Ltd.Inventor: Qun Sun
-
Publication number: 20220370399Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.Type: ApplicationFiled: July 18, 2022Publication date: November 24, 2022Inventor: Qun Sun
-
Publication number: 20220370569Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.Type: ApplicationFiled: August 5, 2022Publication date: November 24, 2022Inventor: Qun Sun
-
Publication number: 20220361551Abstract: A fully automatic peanuts peeling robot for seeds retention and a method using the same are provided. The robot includes a processing mechanism, a feeding mechanism and a screening mechanism. The processing mechanism includes an aluminum profile support bracket, a bracket assembly, a conveyor belt device, and a conversion device, a sensor device and a cut-off device; the aluminum profile support bracket is fixedly connected to the bracket assembly; the bracket assembly includes a first bracket assembly, a second bracket assembly, and a third bracket assembly; and the aluminum profile support bracket is fixedly connected to the conveyor belt device; the conveyor belt device includes a first conveyor belt assembly, a second conveyor belt assembly, and a third conveyor belt assembly; the conveyor belt device is fixedly connected to the conversion device.Type: ApplicationFiled: April 14, 2021Publication date: November 17, 2022Applicant: Liaocheng UniversityInventors: Qun Sun, Fuguo Ren, Ying Zhao, Dongjie Zhao
-
Publication number: 20220362205Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.Type: ApplicationFiled: July 26, 2022Publication date: November 17, 2022Inventor: Qun Sun
-
Patent number: 11475879Abstract: Text content is determined. The text content is input to a content classifying model. The content classifying model is adapted to determine a probability of the text content belonging to a category. An evaluated value of quality of the text content is determined according to the probability of the category and a weight of the category. The weight represents importance of the category.Type: GrantFiled: August 14, 2020Date of Patent: October 18, 2022Assignee: Beijing Xiaomi Pinecone Electronics Co., Ltd.Inventors: Xiao Lu, Qun Guo, Erli Meng, Bin Wang, Hongxu Ji, Lei Sun
-
Patent number: 11459321Abstract: Novel thiazole- and isoquinoline-containing compounds are presented that are useful for treating and/or preventing broad-spectrum viral infections. Methods of treating and/or preventing broad-spectrum viral infections are also presented. These compounds have shown inhibition of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.Type: GrantFiled: October 17, 2018Date of Patent: October 4, 2022Assignee: Evrys Bio, LLCInventors: Stacy Remiszewski, Lillian W. Chiang, Eain Anthony Murphy, Qun Sun, Frank Kayser, Sarah Jocelyn Fink
-
Publication number: 20220278860Abstract: A system, a method and a device for developing a smart contract are provided. A particular embodiment of the system comprises a specification acquisition module configured to acquire specification of a target smart contract interface, a client development module configured to generate, on the basis of the specification of the target smart contract interface, a smart contract client side interface and a smart contract client side agent, the smart contract client side interface and the smart contract client side agent being used to construct a client smart contract application, and a server development module configured to generate, on the basis of the interface specification of the target smart contract, a smart contract server interface and a smart contract server skeleton, the smart contract server interface and the smart contract server skeleton being used to construct a server smart contract.Type: ApplicationFiled: April 1, 2020Publication date: September 1, 2022Applicant: Jingdong Technology Information Technology Co., Ltd.Inventors: Chao Ma, Ming Zhao, Chunwei Liu, Yi Wang, Qun Lin, Haibo Sun
-
Patent number: 11419842Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.Type: GrantFiled: October 27, 2017Date of Patent: August 23, 2022Assignee: Zhuhai Beihai Biotech Co., Ltd.Inventor: Qun Sun
-
Patent number: 11413265Abstract: This document relates to a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, wherein the human serum albumin and the Cabazitaxel, or a pharmaceutically acceptable salt thereof, in the composition have a ratio by weight of no less than 120:1. This document also relates to methods to prepare a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, as described herein.Type: GrantFiled: April 19, 2019Date of Patent: August 16, 2022Assignee: Zhuhai Beihai Biotech Co., Ltd.Inventor: Qun Sun
-
Publication number: 20220226444Abstract: This document relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, and human serum albumin, wherein the fosaprepitant, or a pharmaceutically acceptable salt thereof, and the human serum albumin in the composition have a ratio by weight from about 1:0.1 to about 1:500. This document also relates to a composition comprising aprepitant and human serum albumin, wherein the aprepitant and the human serum albumin in the composition have a ratio by weight from about 1:80 to about 1:1000. This document also relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, aprepitant and human serum albumin.Type: ApplicationFiled: April 5, 2022Publication date: July 21, 2022Inventor: Qun Sun
-
Patent number: 11374404Abstract: Disclosed is a low-voltage DC power distribution fast switching device. The device includes a positive output terminal electrically connected to a positive pole of a load, and no less than two switching circuits connected in parallel with each other; the switching circuit includes a positive input terminal electrically connected to a positive pole of common negative power supplies, a supplementary diode cluster composed of no less than one diode connected in series, and a thyristor connected between the positive input terminal and the positive output terminal; the positive input terminal is electrically connected to an anode of the supplementary diode cluster and an anode of the thyristor, and the positive output terminal is electrically connected to a cathode of the complementary diode cluster and a cathode of the thyristor.Type: GrantFiled: August 26, 2020Date of Patent: June 28, 2022Assignees: State Grid Jiangsu Electric Power Co., Ltd. Research Institute, State Grid Corporation of China, State Grid Jiangsu Electric Power Co., Ltd., Jiangsu Electric Power Research Institute Co., Ltd.Inventors: Yubo Yuan, Tiankui Sun, Jinggang Yang, Xiaodong Yuan, Lei Gao, Mingming Shi, Peng Li, Wei Su, Kun Yang, Xinyao Si, Jianhua Qin, Xin Fang, Xiaolong Xiao, Ruihuang Liu, Chenqing Wang, Jiahao Guo, Yunlong Jiang, Shuyi Zhuang, Qun Li, Jian Liu, Shu Chen
-
Patent number: 11358961Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.Type: GrantFiled: December 22, 2019Date of Patent: June 14, 2022Assignee: Evrys Bio, LLCInventors: Stacy Remiszewski, Emre Koyuncu, Qun Sun, Lillian Chiang
-
Publication number: 20220135556Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.Type: ApplicationFiled: January 13, 2022Publication date: May 5, 2022Applicant: Evrys Bio, LLCInventors: Stacy Remiszewski, Emre Koyuncu, Qun Sun, Lillian Chiang
-
Publication number: 20210386741Abstract: This document relates to compositions comprising a non-covalently bound complex comprising ibrutinib and human serum albumin, wherein the ibrutinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions comprising ibrutinib and human serum albumin, wherein the ibrutinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions consisting essentially of ibrutinib and human serum albumin, wherein the ibrutinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000.Type: ApplicationFiled: August 18, 2017Publication date: December 16, 2021Inventor: Qun Sun
-
Publication number: 20210139475Abstract: Novel thiazole- and isoquinoline-containing compounds are presented that are useful for treating and/or preventing broad-spectrum viral infections. Methods of treating and/or preventing broad-specturm viral infections are also presented. These compounds have shown inhibition of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.Type: ApplicationFiled: October 17, 2018Publication date: May 13, 2021Applicant: Evrys Bio, LLCInventors: Stacy Remiszewski, Lillian W. Chiang, Eain Anthony Murphy, Qun Sun, Frank Kayser, Sarah Jocelyn Fink
-
Patent number: 10980792Abstract: This document relates to compositions comprising a non-covalently bound complex comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions consisting essentially of cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000.Type: GrantFiled: September 11, 2017Date of Patent: April 20, 2021Inventor: Qun Sun
-
Publication number: 20210052540Abstract: This document relates to a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, wherein the human serum albumin and the Cabazitaxel, or a pharmaceutically acceptable salt thereof, in the composition have a ratio by weight of no less than 120:1. This document also relates to methods to prepare a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, as described herein.Type: ApplicationFiled: April 19, 2019Publication date: February 25, 2021Inventor: Qun Sun
-
Publication number: 20210040049Abstract: This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.Type: ApplicationFiled: June 21, 2020Publication date: February 11, 2021Applicant: Evrys Bio, LLCInventors: Stacy Remiszewski, Emre Koyuncu, Qun Sun, Lillian Chiang
-
Publication number: 20210023041Abstract: This document relates to a composition comprising Docetaxel, human serum albumin, and one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1. This document also relates to a composition comprising Docetaxel, human serum albumin, one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, and a sugar alcohol or a sugar, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1.Type: ApplicationFiled: April 11, 2019Publication date: January 28, 2021Inventor: Qun Sun